scholarly journals Skin Metastasis in Breast Cancer Patients; a Case Series

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Sara Rehman ◽  
Muhammad Atif Naveed
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Conservation ◽  
Case Series ◽  
Recurrent Breast Cancer ◽  
Skin Lesions ◽  
Skin Metastasis ◽  
Research Centre ◽  
Breast Cancer Patients ◽  
Retrospective Case

Introduction: Breast cancer is the most common malignancy in women. It frequently metastasizes to bones, lungs and liver. Although rare, skin metastasis may also take place. It may also be the presenting feature of initial or recurrent breast cancer. The assessment of recurrent metastatic disease involving skin after mastectomy can be challenging because of the benign-appearing clinical presentation. The purpose of this caseseries was to explore the clinical and radiological presentation of skin metastasis in patients of breast cancer. Materials and Methods: This is a retrospective case series of breast cancer patients with skin lesions on chest and abdomen at the time of initial presentation, or post-treatment such as, after mastectomy or breast conservation therapy; who underwent various radiological investigations including mammography, ultrasoundscan, computed tomography (CT) scan and magnetic resonance imaging from 1 May 2018 to 30 September 2019 at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. Results: A total of eightcases were identified, out of which seven were females. The most common presentation consisted of the presence of metastatic nodules which were seen in 62.5% (five out of eight) of the patients. Other features consisted of erythematous or plaque-like skin thickening on clinical examination, increased density with indistinct margins seen on a mammogram and diffuse oedematous changes in the skin with small irregular mass or infiltration into subcutaneous tissues were visualised on ultrasound and CT studies. Conclusion: Skin metastasis from breast cancer most commonly presents as nodules, although rarely they may present as plaques or diffuse skin thickening. Awareness of diverse manifestations of skin metastasis is of utmost importance in early diagnosis and management.

Survival time in urban center breast cancer patients with CNS metastasis with or without visceral metastasis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1088-1088
Author(s):  
Miriam Pearl Klahr ◽  
Junwen Deng ◽  
Jesus Del Santo Anampa Mesias
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Case Series ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Retrospective Case ◽  
Cns Metastasis ◽  
Case Series Study

1088 Background: There is limited data about the role of isolated central nervous system (CNS) metastasis (mets) in patients with breast cancer (BC), since prior studies evaluated BC patients with CNS plus visceral mets. Furthermore, though Black race is associated with worse BC outcomes, there are few studies on CNS mets that predominantly included racial and ethnic minorities in their cohorts. Our study compares overall survival (OS) in BC patients with CNS involvement with and without visceral mets in an underrepresented patient population. Methods: This is a retrospective case series study. We used Montefiore’s Clinical Looking Glass software to identify patients. Inclusion criteria were females age ≥18 years at our institution with the diagnosis of BC and CNS mets between 3/31/1997 to 3/31/2019. Chart review was conducted to obtain clinical-pathological features, including date of diagnosis, treatment, clinical course, and survival status. Patients with BC and CNS mets were divided into two cohorts, those with additional mets limited to bone and lymph nodes but without further visceral spread (CNS-NV), and those with CNS mets plus visceral mets (CNS-V). Kaplan-Meier methods were used to analyze the median OS. Results: Our study included a high proportion of underrepresented minorities (n=177); 46.3% were Black, 10.7% were White, and 34.5% were Other Race; besides, 28% were Hispanic. Mean age at diagnosis of CNS mets was 58 years (SD = 12.9). 62.1% were estrogen receptor (ER) and/or progesterone receptor (PR) positive, 27.1% were HER2 positive; and 19.8% were ER, PR and HER2 negative. Mean number of chemotherapy and endocrine therapy lines before CNS mets were 2 (IQR = 1-2) and 1 (IQR = 1-2), respectively. CNS-NV and CNS-V cohorts included 35 and 142 patients, respectively. Patients with CNS-NV had longer OS than CNS-V (2118 vs. 1120 days, p=0.02). Further subgroup analysis for group CNS-NV was performed based on treatment modality. In this cohort, OS was not significantly different between patients who did and did not receive chemotherapy (n =35, mean OS 1509 vs. 960 days, p = 0.49). In addition, OS was not significantly different between patients who received and did not receive endocrine therapy (n = 24, mean OS 857 vs. 1394 days, p = 0.4). Finally, OS did not significantly differ between patients who did and did not receive anti HER2 treatment (n = 11, 1753 vs. 849 days, p = 0.15). Conclusions: Minimal research has been conducted on breast cancer patients with CNS mets and distal involvement limited to the bones or lymph nodes. In a heterogenous racial and ethnic population, patients with BC and CNS mets have prolonged OS if the extent of distal involvement is limited to the bones or lymph nodes, compared to those with visceral mets. More research with larger sample sizes is needed to confirm our findings, which may help to de-escalate and tailor treatment for patients with CNS mets.

scholarly journals Perioperative interstitial CT-based brachytherapy boost in breast cancer patients with breast conservation after neoadjuvant chemotherapy

Neoplasma ◽  
2012 ◽  
Vol 59 (05) ◽  
pp. 494-499 ◽  
Author(s):  
M. DOLEZEL ◽  
K. STASTNY ◽  
K. ODRAZKA ◽  
J. VANASEK ◽  
T. KOHLOVA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Conservation ◽  
Breast Cancer Patients ◽  
Brachytherapy Boost

Breast-conservation therapy in early-stage breast cancer patients with a positive family history

2002 ◽  
Vol 9 (9) ◽  
pp. 912-919 ◽  
Author(s):  
Georges Vlastos ◽  
Nadeem Q. Mirza ◽  
Funda Meric ◽  
Kelly K. Hunt ◽  
Attiqa N. Mirza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Cancer Patients ◽  
Early Stage ◽  
Positive Family History ◽  
Breast Conservation ◽  
Breast Conservation Therapy ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients

Axillary Regional Recurrence after Sentinel Lymph Node Biopsy for Breast Cancer

2006 ◽  
Vol 72 (10) ◽  
pp. 939-942
Author(s):  
David K. Rosing ◽  
Christine E. Dauphine ◽  
M. Perla Vargas ◽  
Katherine Gonzalez ◽  
Melissa Burla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Cancer Patients ◽  
Axillary Dissection ◽  
Breast Conservation ◽  
Lymph Node Biopsy ◽  
Breast Cancer Patients ◽  
Node Biopsy

The accuracy of sentinel lymph node biopsy (SLNB) staging in breast cancer has been demonstrated in studies comparing it with axillary dissection. There is a 5 per cent false-negative rate, but this does not always correlate with axillary recurrence. Our purpose was to determine the rate of axillary lymphatic recurrence in breast cancer patients who had a negative SLNB. We conducted a cohort study of breast cancer patients who underwent SLNB between 2001 and 2005. Only patients who had a negative SLNB were included. Patient demographics and tumor factors were reviewed. Outcomes measured were axillary and systemic recurrence and survival. Eighty-nine patients with a mean age of 54.4 ± 9.9 years were included. Eighty-nine per cent of cases had infiltrating ductal carcinoma histology. Mean tumor size was 19 ± 14 mm. Breast conservation surgery was done in 65 cases and mastectomy in 24. A mean of 2.3 ± 2.4 SLN were found. After a median follow-up of 2.15 years, 1 (1%) patient developed a lymphatic recurrence in the axilla. SLNB provides accurate staging of breast cancer. Patients with negative SLNB do not require axillary dissection.

Hypofractionation with no boost after breast conservation in early-stage breast cancer patients

2016 ◽  
Vol 33 (10) ◽  
Author(s):  
Francesca Arcadipane ◽  
Pierfrancesco Franco ◽  
Chiara De Colle ◽  
Nadia Rondi ◽  
Jacopo Di Muzio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Breast Conservation ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document